- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Urothelial carcinoma is a type of cancer that typically occurs in the urinary system. It begins in specific cells that are called urothelial cells. These cells line the urethra, bladder, ureters, renal pelvis, and some other organs. Urothelial cells are also called transitional cells. These cells can change shape and stretch without breaking apart.
Showing all 3 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
PD-L1 |
Monoclonal Antibody-Fc engineered |
Tecentriq® |
60 mg/mL |
yes |
12 mg |
-80°C |
2022.03 |
262,80 € |
||
PD-L1 |
Monoclonal Antibody-Fc engineered |
Tecentriq® |
60 mg/mL |
yes |
12 mg |
-80°C |
2023.05 |
262,80 € |
||
PD-L1 |
Monoclonal Antibody |
Bavencio® |
20 mg/mL |
– |
2 mg |
-80°C |
2021.01 |
125,10 € |
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany